

In the Claims

1-13. (Canceled)

14. (New) A method of treating Severe Acute Respiratory Syndrome (SARS) comprising the administration of a composition comprising an interferon (IFN) to an individual having SARS.

15. (New) The method according to claim 14, wherein said composition comprises an IFN in combination with an antiviral agent.

16. (New) The method according to claim 15, wherein said antiviral agent is Ribavirin.

17. (New) The method according to claim 14, wherein said IFN is recombinant human IFN-beta.

18. (New) The method according to claim 14, wherein said IFN is consensus interferon.

19. (New) The method according to claim 15, wherein said IFN is recombinant human IFN-beta.

20. (New) The method according to claim 15, wherein said IFN is consensus interferon.

21. (New) The method according to claim 14, wherein said IFN is a fused protein comprising at least an immunoglobulin domain.

22. (New) The method according to claim 15, wherein said IFN is a fused protein comprising at least an immunoglobulin domain.

23. (New) The method according to claim 17, wherein said IFN is a fused protein comprising at least an immunoglobulin domain.

24. (New) The method according to claim 18, wherein said IFN is a fused protein comprising at least an immunoglobulin domain.

25. (New) The method according to claim 14, wherein said IFN is administered at a dosage of about 1 to 50 μg per person per day, or about 10 to 30 μg per person per day or about 10 to 20 μg per person per day.

26. (New) The method according to claim 14, wherein said IFN is administered daily or every other day.

27. (New) The method according to claim 14, wherein said IFN is administered twice or three times per week.

28. (New) The method according to claim 14, wherein said IFN is administered subcutaneously.

29. (New) The method according to claim 14, wherein said IFN is administered intramuscularly.

30. (New) The method according to claim 15, wherein the antiviral agent is administered at a dosage of about 100 to 2000 mg per person per day, or about 400 to 1200 mg per person per day, or about 800 to 1000 mg per person per day, or about 1000 to 1200 mg per person per day.

31. (New) The method according to claim 16, wherein Ribavirin is administered orally.

32. (New) The method according to claim 14, wherein said method further comprises the administration of a composition comprising an antiviral agent to said individual.

33. (New) The method according to claim 32, wherein said composition is administered simultaneously, sequentially or separately from a composition comprising an IFN.

34. (New) The method according to claim 32, wherein said antiviral agent is Ribavirin.

35. (New) The method according to claim 34, wherein said antiviral agent is administered at a dosage of about 100 to 2000 mg per person per day, or about 400 to 1200 mg per person per day, or about 800 to 1000 mg per person per day, or about 1000 to 1200 mg per person per day.

36. (New) The method according to claim 35, wherein said antiviral agent is administered orally.